Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2025-11-16. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 is a synthetic analogue of growth hormone-releasing hormone, built on the 29-amino-acid GHRH(1-29) fragment. Four substitutions distinguish it from the natural sequence: D-alanine at position 2, glutamine at position 8, alanine at position 15, and leucine at position 27. These changes reduce enzymatic cleavage and extend the peptide's persistence in circulation. The compound is discussed in two forms, one carrying a drug affinity complex and one without it.
The drug affinity complex is a maleimidopropionic acid group attached to a lysine side chain. It reacts with the free thiol of cysteine-34 on circulating albumin, forming a covalent bond. This conjugation keeps the peptide in the bloodstream and shields it from rapid renal filtration and proteolysis. Reported circulation half-lives for the albumin-bound form fall in the range of roughly six to nine days in early human studies.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
The second form adds a maleimide-bearing linker to the lysine at the carboxyl end. This group reacts with cysteine-34 on circulating serum albumin, forming a covalent bond that keeps the peptide in the bloodstream for far longer. ConjuChem developed the molecule as a way to extend the action of a peptide without frequent administration. The albumin attachment is the defining structural feature of the drug affinity complex version. Whether continuous exposure produces effects distinct from shorter pulses remains an unresolved research question.
=== Education === Kopeček graduated with his M.S. in macromolecular chemistry from the Institute of Chemical Technology in Prague, Czechoslovakia, in 1961. He then received his Ph.D. in macromolecular chemistry from the Institute of Macromolecular Chemistry at the Czechoslovak Academy of Sciences in Prague in 1965. In 1967, Kopeček pursued postdoctoral studies at the National Research Council of Canada in the Division of Applied Chemistry in Ottawa. In 1990 Kopeček received his D.Sc. in chemistry from the Czechoslovak Academy of Sciences. During his time in graduate school, he was mentored by professors Drahoslav Lim and Otto Wichterle, who invented hydrogels and created soft contact lenses. Kopeček received an honorary Ph.D. from the University of Helsinki in Finland in 2014.
The angiotensin II receptors, (ATR1) and (ATR2), are a class of G protein-coupled receptors with angiotensin II as their ligands. They are important in the renin–angiotensin system: they are responsible for the signal transduction of the vasoconstricting stimulus of the main effector hormone, angiotensin II. The AT1 and AT2 receptors share a sequence identity of ~30%, but have a similar affinity for angiotensin II, which is their main ligand. The AT1 receptor is the best elucidated angiotensin receptor. The AT1 subtype is found in the heart, blood vessels, kidney, adrenal cortex, lung and circumventricular organs of brain, basal ganglia, brainstem and mediates the vasoconstrictor effects. The angiotensin receptor is activated by the vasoconstricting peptide angiotensin II. The activated receptor in turn couples to Gq/11 and Gi/o and thus activates phospholipase C and increases the cytosolic Ca2+ concentrations, which in turn triggers cellular responses such as stimulation of protein kinase C. Activated receptor also inhibits adenylate cyclase and activates various tyrosine kinases.
=== Meckel's diverticulum === Pertechnetate is actively accumulated and secreted by the mucoid cells of the gastric mucosa, and therefore, technetate(VII) radiolabeled with Tc99m is injected into the body when looking for ectopic gastric tissue as is found in a Meckel's diverticulum with Meckel's Scans.
Sources: en.wikipedia.org
It was armed with four .30 caliber (7.62 mm) AN/M2 Browning machine guns in the wings and two .50 caliber (12.7 mm) AN/M2 Browning machine guns mounted under the engine and firing through the propeller arc using a gun-synchronizing gear. While the USAAC could block any sales it considered detrimental to the interests of the US, the NA-73 was considered to be a special case because it had been designed at the behest of the British and all dealings were directly between the BPC and NAA, and did not involve the US Army or Wright Field in any way. In September 1940, a further 300 NA-73s were ordered by the MAP. To ensure uninterrupted delivery, Colonel Oliver P. Echols arranged with the Anglo-French Purchasing Commission to deliver the aircraft and NAA gave two examples (41-038 and 41-039) to the USAAC for evaluation. The Mustang I (NA-73 and NA-83) and the Ia (NA-91), produced for the British, were not equivalent to the P-51A which was a later model (NA-99). Two British Mustang Is were held back by the USAAF and given the provisional model number XP-51. The USAAF held back 57 Mustang Ia aircraft armed with 4 x 20mm Hispano cannon, from the third British order, converting most of them to tactical reconnaissance aircraft and designating them P-51-2/F6A. North American retained the second aircraft of this batch to help develop the P-51A. The Allison engine in the Mustang I had a single-stage supercharger that caused power to drop off rapidly above 15,000 feet (4,600 m). This made it unsuitable for use at the altitudes where combat was taking place in Europe.
==== MeSH D12.125.119 – amino acids, dicarboxylic ==== MeSH D12.125.119.075 – 2-aminoadipic acid MeSH D12.125.119.170 – aspartic acid MeSH D12.125.119.170.150 – d-aspartic acid MeSH D12.125.119.170.275 – isoaspartic acid MeSH D12.125.119.170.400 – n-methylaspartate MeSH D12.125.119.170.700 – potassium magnesium aspartate MeSH D12.125.119.270 – carbocysteine MeSH D12.125.119.307 – cystathionine MeSH D12.125.119.369 – cystine MeSH D12.125.119.450 – glutamic acid MeSH D12.125.119.450.150 – 1-carboxyglutamic acid MeSH D12.125.119.450.400 – glutamates MeSH D12.125.119.450.400.700 – polyglutamic acid MeSH D12.125.119.450.400.800 – sodium glutamate MeSH D12.125.119.658 – homocystine
UNC Rex Hospital is a general hospital located in Raleigh, North Carolina. It is the capital city's oldest hospital, founded by a bequest from John T. Rex (1771–1839), a local tanner, planter, and owner of enslaved families, and named in his honor. Originally located on what is now Dorothea Dix campus, and later on St. Mary's Street, Rex is now located in west Raleigh at the corner of Blue Ridge Road and Lake Boone Trail. Rex Health Care's services include oncology, heart and vascular, surgical services (including bariatric, heartburn, GI, orthopedic, neuro, and spinal), rehabilitation, emergency department, urgent care, women's services, and wound healing. Rex is a member of the UNC Health Care system, a non-profit integrated health care system, owned by the state of North Carolina and based in Chapel Hill, North Carolina. Rex is located just 2 miles from the Lenovo Center, and is the official healthcare provider of the Carolina Hurricanes and NC State Wolfpack.
Sources: en.wikipedia.org
=== Israel trip === During a July 2026 trip to Israel, Chabad "outreach figure" Yossi Farro presented Peters with a "custom necklace" which shows the Star of David fused with the OpenAI logo. The moment was considered the "latest flashpoint" in a debate over how the Jewish community should engage with controversial online figures. Farro joked online that the "mashup" amounted to the AI company's logo "mogging" the Jewish star. The two switched restaurants mid-meal once Peters realized the one they had chosen was not kosher. Farro posted about the trip, saying Peters "is loving Israel and Israel is loving him." "Peters's manager is Jewish," Farro further explained, "and the rabbi of the Chabad community connected to the manager thought it would be worthwhile to introduce us. Thank God, we connected." The Times of Israel reported that Peters had been seen talking to prime minister Benjamin Netanyahu's adviser Topaz Luk at a Tel Aviv nightclub. Israeli influencers who appeared on Peters's streams, Shira Braun and Shira Klein, were reprimanded and demoted from their positions by the Israel Defense Forces.
==== Adrenal medulla ==== By binding to ganglion type nicotinic receptors in the adrenal medulla, nicotine increases flow of adrenaline (epinephrine), a stimulating hormone and neurotransmitter. By binding to the receptors, it causes cell depolarization and an influx of calcium through voltage-gated calcium channels. Calcium triggers the exocytosis of chromaffin granules and thus the release of epinephrine (and norepinephrine) into the bloodstream. The release of epinephrine (adrenaline) causes an increase in heart rate, blood pressure and respiration, as well as higher blood glucose levels.
== Interactions == Heparin-binding EGF-like growth factor has been shown to interact with NRD1, Zinc finger and BTB domain-containing protein 16 and BAG1. HB-EGF biological activities with these genes influence cell cycle progression, molecular chaperone regulation, cell survival, cellular functions, adhesion, and mediation of cell migration. The NRD1 gene codes for the protein nardilysin, an HB-EGF modulator. Zinc finger and BTB domain-containing protein 16 and BAG family molecular chaperone regulator function as co-chaperone proteins in processes involving HB-EGF.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
A maleimide moiety reacts with the thiol of cysteine-34, forming a covalent bond. The reaction occurs in circulation without enzymatic catalysis.